Prime Medicine Announces FDA Clearance Of IND Application For Pm359
Prime Medicine, Inc. (PRME) announced the FDA has cleared the company's Investigational New Drug application for PM359 for the treatment of chronic granulomatous disease, enabling the company to initiate global Phase 1/2 clinical trial in the United States.